Compare NNNN & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | ENOV |
|---|---|---|
| Founded | 2021 | 1995 |
| Country | Germany | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | N/A | 2008 |
| Metric | NNNN | ENOV |
|---|---|---|
| Price | $25.50 | $26.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $47.38 |
| AVG Volume (30 Days) | 12.8K | ★ 808.1K |
| Earning Date | 04-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.36 |
| Revenue Next Year | N/A | $5.31 |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.03 | $21.00 |
| 52 Week High | $55.65 | $36.82 |
| Indicator | NNNN | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 61.47 |
| Support Level | $26.31 | $26.29 |
| Resistance Level | $30.21 | $26.72 |
| Average True Range (ATR) | 2.10 | 1.50 |
| MACD | -0.28 | 0.28 |
| Stochastic Oscillator | 20.78 | 77.57 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.